{"name":"Vor Biopharma","slug":"vor","ticker":"VOR","exchange":"NASDAQ","domain":"vorbiopharma.com","description":"Vor Biopharma is a biotechnology company focused on developing cell and gene therapies for hematologic oncology. The company's pipeline includes several promising candidates, including VOR33, a CAR-T cell therapy for B-cell malignancies. Vor Biopharma is positioning itself as a leader in the cell and gene therapy space, with a strong focus on innovation and patient outcomes. The company's pipeline and technology have generated significant interest among investors and the scientific community.","hq":"Cambridge, MA, USA","founded":0,"employees":"","ceo":"Robert Ang","sector":"Cell & Gene Therapy / Hematologic Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$210M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":321532000,"netIncome":-695981000,"cash":396486000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"VOR33 patent cliff ($0.0B at risk)","drug":"VOR33","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Vor Biopharma Announces FDA Clearance of IND for VOR33","summary":"Vor Biopharma announced that the FDA has cleared the Investigational New Drug (IND) application for VOR33, a CAR-T cell therapy for B-cell malignancies.","drugName":"VOR33","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Vor Biopharma Reports Third Quarter 2023 Financial Results","summary":"Vor Biopharma reported its third quarter 2023 financial results, highlighting progress in its pipeline and financial performance.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Vor Biopharma Announces Collaboration with Leading Cancer Research Institute","summary":"Vor Biopharma announced a collaboration with a leading cancer research institute to advance its cell and gene therapy pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOcUZYRE00dXpJVGljUW11TkN4TU1zMGZOUE8xdmNVd0hQcGRDUVh0VVF3N3NaWnkwaUJOekdqZjNxQm1qVzduSS0zTllBTmRGNXdTYVo3clQydVkydUdsX0ttRUhKLVljVmlzS0VYU0doVWhsR0ZBQVNXazRGQWlDZVFDd2lZdUR6MkpuRGd6ZWs5U3I3LXEyc1dqOHFTaExfemc?oc=5","date":"2025-09-25","type":"deal","source":"Seeking Alpha","summary":"Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise - Seeking Alpha","headline":"Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPWTFxc1Y3RzFheFp1OFpjbjRTWnFLYWFsUzh4TWVTREZ3dGdXTVBtR0ptSHE0S3hhREtxTFlTRktGYXJ1d1hDQl9kbllUeUN2NUpYVjhPaV9jS3I1Q0tveHBJSG9zLTNWZmMtWGxFZi1LVFR0UHFtNXl3eXZGY0JKeTc2MThmZGo5VG1rT0Fn?oc=5","date":"2025-08-11","type":"pipeline","source":"The Pharma Letter","summary":"Vor Bio lures Sarepta exec to be its CCO - The Pharma Letter","headline":"Vor Bio lures Sarepta exec to be its CCO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1rNkhUMVk2QjJudXZROERwZmRMeUdDUlM1ZVpGd3JZdGJWNmV0aUhZYXBsbjIwSkpSR3VWbTB5ckU5Qy1vSTE3LXRicGtvV096Z0NKX0dtT1ZtV2trdTNNTUs2Z1Q0dmF0c3pPTS1WUEZoUF91MXdXU0gwY1ZyTk0?oc=5","date":"2025-06-30","type":"pipeline","source":"Yahoo Finance","summary":"Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why - Yahoo Finance","headline":"Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNclpRSGx0Z014ai1mU1VJYWptV1FNUlNLYWdiLWdRMWpOTUJMV21TX3c3WDV5NDF5bUtHTXV1dDcxTGkyY1RMaElDWHNDVFA0cl9nYlJsUGxtOUJ2STYySVotU05iZVFPRThscC10WFB1blQtTlZsaFU3bjB0UnJ3cWNPZGxvalFvcExhb1djRklzM2k4QklqUDdSLTlNenhxQnM2bG14WnUzQzlwX2tMbWFhSDFncXIyM1l3Y0VfQW54R0FYekE?oc=5","date":"2025-06-26","type":"deal","source":"Fierce Pharma","summary":"Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions - Fierce Pharma","headline":"Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNY2tfTzVoTzV3MmlWLTJRODFfSThONVhLQjBFQzdEM3pfc3h3bzc1MGhnRm13LTJYQ0FfOTFrVGgwT01CdGZHd1Z5dTJ0eDlJV2o0RmRKX0pQNVZKbnh2YnhFbjctRXRiUWFaam9hYXk0R0tNaWt5UlFMVk5PN3d1UkJyZw?oc=5","date":"2025-06-26","type":"pipeline","source":"BioPharma Dive","summary":"Vor, with new CEO, changes course to target autoimmune disease - BioPharma Dive","headline":"Vor, with new CEO, changes course to target autoimmune disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPbnNkR200QnB3WlE0Y21razIzQy1MbjRMLUM2Q0VXMkFHUlJKNGRfY2VjSGlEeURrMmdNbzMxWHhYeDV5eTB4Q2dnUVRlZ2ZPNlpLZmNKZWx5VGl4MWt4aDlFMU9qNTViS0xtbkIyakF5aGxud3BMX2tLQjJXS3phVWV4M2NFYnM1NWgwTGljeHdSLVFhSER5cHlqS0puV0ZrT1h3cE4tdWxqSkZrcXhlMg?oc=5","date":"2025-06-26","type":"deal","source":"Pharmaceutical Technology","summary":"Vor Bio back from brink with autoimmune drug deal rising to $4bn - Pharmaceutical Technology","headline":"Vor Bio back from brink with autoimmune drug deal rising to $4bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPa1c2VkNnS0NCOVBEYkdYMHlOdUFueDVuWkdJUldkX2haNWxwamZOMEMwbU1nR0xEeUhtS040VE14UzRqQVNBbE81X1FNc21aN2pjWi1aSlFaelE5ZFpYNGJaMDREOGZHVVVLbGpWb0ZhQXdJLWtQdUc1RURLdjRjWFBRNGdJNU1pLWE4QWpnQ1pqa01QQ3VYUjhPQkExMzczaW53alZ4MEdqZTJjLWdVMEh4c3JGQQ?oc=5","date":"2025-06-26","type":"trial","source":"MedCity News","summary":"Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding - MedCity News","headline":"Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQV3lOU1FDekVqQ0J4MkNORDEta0hFT1NwT2xUb1daMGxReFE2a1otc0ZIX1ZfbmEyMXVMckdNSklzUGhVUWF6d3VLUXNnZmdMNjRSdXZ1T2kyR2xjejJQYjRsU0M4RXVvSU42RGtJYmNPQlJId0M2U3E1b1pZZ1VDd092cHhUQQ?oc=5","date":"2025-06-26","type":"deal","source":"pharmaphorum","summary":"Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen - pharmaphorum","headline":"Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxORGJHUDc3ZzE2dU1ZLUhXaFE5cFp4NUlZMjdGR2s4b2dMSlR4RjRSMjRGdEUxemFOVUYyTWo4NldiU19NNWVHaDVteks4UWthNWlud3c3aUpzaUxfMGZuRTB4eUtzSEYtUXpCdFQ1OWVkd3ZBYWZTY0ZjM1B1Y19kOGNCbjZObXpkMEhFcUxsRjBhbEpGS1dsYlNZQmdzUGVWR001MW1CbHoyX3RpaFc4N3JTTzdoS2JsbjMtd1V2OUxkUUE2a00xc2F6S2lFRlFRbl9GTWN0bTZJNnBoc2gtcWFUcTdnNVFhV3VWNEprMXBZR1U4cFZpaS1MRlZLM2tT?oc=5","date":"2025-06-25","type":"deal","source":"GlobeNewswire","summary":"Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - GlobeNewswire","headline":"Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQWkx1UWVMS1luR1dTQ3RLSTMwTllUcm9jNFlQZWZxN1NUOFdWRk5tcW1EalRDZE9ST1VBVnZxZTllTGpKaVF4R0t3WHVUX2x6SFFteldDY2lqcnFRaWZrWl8wTXg4bUxiaS1EMW1SbkE5Y2JLVVlGNmlZVEZNbUZvNk44RnpDTHlHZ2lZNnYzWDlCdHUyVXQ0WmFmMzZfODFhal9BS01nTGRDMXI1b0VzUlgxNjhndXBPcU9pT05PRDVkMkhjQ3lqZ0FWZw?oc=5","date":"2025-05-27","type":"pipeline","source":"Investing.com","summary":"Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options - Investing.com","headline":"Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5iQmNJZk9HS09QTUxQaXowVDM3MkpCbU9velBONWpNbnR3QmVZNklEdDh5NWphWHZuX0NYX1N0ZXQ2U2FzcDMxVklQMXNvcERlenlr?oc=5","date":"2025-05-08","type":"pipeline","source":"firstwordpharma.com","summary":"Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio - firstwordpharma.com","headline":"Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio","sentiment":"neutral"}],"patents":[{"drugName":"VOR33","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Novartis"],"therapeuticFocus":["Hematologic Oncology","Cell and Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":321532000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-695981000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":396486000,"cashHistory":[],"totalAssets":464126000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}